Japanese | English

トップページへ戻る

詳細

   
フルテキストURLフルテキストリンクなし
タイトルContinuous Ambulatory Pertoneal Dialysis(CAPD)患者の腎性貧血に対するRrecombinant human erythropoitin の使用経験
タイトルヨミContinuous Ambulatory Pertoneal Dialysis(CAPD) カンジャ ノ ジンセイ ヒンケツ ニ タイスル Rrecombinant human erythropoitin ノ シヨウ ケイケン
タイトル別表記Intravenous Administration of Recombinant Human Erythropoietin (EPO) for Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients
作成者土田, 昌弘
竹本, 雅彦
小西, 基彦
須賀, 昭信
城嶋, 和孝
内藤, 克輔
作成者ヨミツチダ, マサヒロ
タケモト, マサヒコ
コニシ, モトヒコ
スガ, アキノブ
ジョウジマ, カズタカ
ナイトウ, カツスケ
作成者別表記tsuchida, Masahiro
Takemoto, Masahiko
Konishi, Motohiko
Suga, Akinobu
Jyoushima, Kazutaka
Naitou, Katsusuke
作成者所属山口大学医学部
内容記述(抄録等)Recombinant human erythropoietin (EPO) is an effective agent for the treatment of the anemia of end-stage renal disease. The efficacy of intravenous administration in hemodialysis or CAPD patients has been established. However, especially in CAPD patients, the ideal dosage and mode of administration are not identified yet. We administered a dose of 6000U/bo.dy of EPO once a week to 6 CAPD patients (4 males and 2 females) whose mean age was 42.3 years old. All patients improved their anemia after 12 weeks follow-up. However, the patients whose serum iron or ferritin were low level showed less response to EPO. Four patients needed additional antihypertensive medications. Major side effects were not noted. Subsequently, we ran a second trial. Three patients who did not satisfactorily respond to EPO were switched to the dose of 9000U/body of EPO. Hematocrit incresased higher than those seen in the dose of 6000U in all 4 patients. We conclude that intravenous administration of EPO is very safe and effective for the treatment of the anemia of CAPD patients.
本文言語jpn
主題医学
資料タイプtext
出版者山口大学医学会
出版者ヨミヤマグチ ダイガク イガッカイ
NII資料タイプ学術雑誌論文
査読の有無査読あり
ISSN0513-1731
NCIDAN00243156
学内刊行物(紀要等)山口医学
掲載誌名山口医学
41
5
開始ページ339
終了ページ344
発行日1992-10
著者版/出版社版その他
リポジトリIDB030041000504
地域区分山口大学
URIhttp://www.lib.yamaguchi-u.ac.jp/yunoca/handle/B030041000504